HomeCompareIPSEY vs RYLD

IPSEY vs RYLD: Dividend Comparison 2026

IPSEY yields 0.86% · RYLD yields 12.39%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RYLD wins by $17.3K in total portfolio value
10 years
IPSEY
IPSEY
● Live price
0.86%
Share price
$46.30
Annual div
$0.40
5Y div CAGR
33.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$2,101.14
Full IPSEY calculator →
RYLD
RYLD
● Live price
12.39%
Share price
$14.64
Annual div
$1.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.3K
Annual income
$2,682.98
Full RYLD calculator →

Portfolio growth — IPSEY vs RYLD

📍 RYLD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIPSEYRYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IPSEY + RYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IPSEY pays
RYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IPSEY
Annual income on $10K today (after 15% tax)
$73.26/yr
After 10yr DRIP, annual income (after tax)
$1,785.97/yr
RYLD
Annual income on $10K today (after 15% tax)
$1,053.44/yr
After 10yr DRIP, annual income (after tax)
$2,280.53/yr
At 15% tax rate, RYLD beats the other by $494.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IPSEY + RYLD for your $10,000?

IPSEY: 50%RYLD: 50%
100% RYLD50/50100% IPSEY
Portfolio after 10yr
$36.6K
Annual income
$2,392.06/yr
Blended yield
6.53%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on IPSEY right now

IPSEY
Analyst Ratings
2
Buy
1
Hold
1
Sell
Consensus: Buy
Altman Z
14.0
Piotroski
7/9
RYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IPSEY buys
0
RYLD buys
0
No recent congressional trades found for IPSEY or RYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIPSEYRYLD
Forward yield0.86%12.39%
Annual dividend / share$0.40$1.81
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR33.9%0%
Portfolio after 10y$28.0K$45.3K
Annual income after 10y$2,101.14$2,682.98
Total dividends collected$7.1K$19.4K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: IPSEY vs RYLD ($10,000, DRIP)

YearIPSEY PortfolioIPSEY Income/yrRYLD PortfolioRYLD Income/yrGap
1← crossover$10,815$115.41$11,939$1,239.34$1.1KRYLD
2$11,729$156.20$14,158$1,382.89$2.4KRYLD
3$12,762$211.97$16,682$1,532.59$3.9KRYLD
4$13,944$288.63$19,537$1,687.64$5.6KRYLD
5$15,314$394.64$22,752$1,847.20$7.4KRYLD
6$16,929$542.40$26,355$2,010.43$9.4KRYLD
7$18,864$750.31$30,376$2,176.45$11.5KRYLD
8$21,231$1,046.28$34,847$2,344.43$13.6KRYLD
9$24,191$1,473.60$39,800$2,513.54$15.6KRYLD
10$27,985$2,101.14$45,269$2,682.98$17.3KRYLD

IPSEY vs RYLD: Complete Analysis 2026

IPSEYStock

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

Full IPSEY Calculator →

RYLDETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →
📬

Get this IPSEY vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IPSEY vs SCHDIPSEY vs JEPIIPSEY vs OIPSEY vs KOIPSEY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.